Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 181Colorectal Neoplasms 144Stomach Neoplasms 90Rectal Neoplasms 90Pancreatic Neoplasms 74Neoplasm Metastasis 60Neoplasms 48Colonic Neoplasms 40Esophageal Neoplasms 31Gallbladder Neoplasms 18Biliary Tract Neoplasms 17Bile Duct Neoplasms 17Carcinoma, Hepatocellular 15Triple Negative Breast Neoplasms 13Cholangiocarcinoma 12Adenocarcinoma 12Unspecified Adult Solid Tumor, Protocol Specific 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Liver Neoplasms 10Breast Neoplasms, Male 10Adenocarcinoma Of Esophagus 10Squamous Cell Carcinoma of Head and Neck 9Head and Neck Neoplasms 9Gastrointestinal Neoplasms 9Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Uterine Cervical Neoplasms 5

Interventions

parsaclisib 2MLN 8237 2zanidatamab 1tislelizumab 1tanespimycin 1spartalizumab 1sitravatinib 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1cabiralizumab 1Temozolomide 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1HMPL-013 1Capecitabine 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancies × Capecitabine × Clear all
NCT00083525 2008-01-24

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Heidelberg Pharma AG

Phase 1 Completed
33 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡